Seeing Is Believing

Currently out of the existing stock ratings of Serge Belanger, 451 are a BUY (91.67%), 41 are a HOLD (8.33%).
Analyst Serge Belanger, currently employed at NEEDHAM, carries an average stock price target met ratio of 38.33% that have a potential upside of 73.06% achieved within 285 days.
Serge Belanger’s has documented 953 price targets and ratings displayed on 36 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on XENE, Xenon Pharmaceuticals at 09-Mar-2026.
Analyst best performing recommendations are on GRAY (GRAYBUG VISION).
The best stock recommendation documented was for KALV (KALVISTA PHARMACEUTICALS) at 1/26/2021. The price target of $32 was fulfilled within 14 days with a profit of $15.65 (95.72%) receiving and performance score of 68.37.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 12-Aug-2025
$30
$11.82 (65.02%)
$34
19 days ago
(27-Feb-2026)
6/10 (60%)
$3.51 (13.25%)
263
Hold Since 17-Nov-2023
$32
$13.82 (76.02%)
$63
6 months 20 days ago
(26-Aug-2025)
1/2 (50%)
$1.66 (5.47%)
48
Hold Since 04-Feb-2025
$25
$6.82 (37.51%)
$32
7 months 10 days ago
(08-Aug-2025)
11/17 (64.71%)
$1.19 (5.00%)
307
Buy Since 20-Oct-2022
$55
$36.82 (202.53%)
$62
1 years 7 months 6 days ago
(12-Aug-2024)
2/5 (40%)
$11.75 (27.17%)
105
Hold Since 08-Jan-2021
$44
$25.82 (142.02%)
$40
2 years 10 months 1 days ago
(17-May-2023)
5/5 (100%)
$1.03 (2.40%)
86
Which stock is Serge Belanger is most bullish on?
Which stock is Serge Belanger is most reserved on?
What Year was the first public recommendation made by Serge Belanger?